A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2011
12/15/2011	US20110306584 Porphyrin Catalysts and Methods of Use Thereof
12/15/2011	US20110306572 COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2]
12/15/2011	US20110306571 Methods for treating cancer
12/15/2011	US20110306570 Na/K-Atpase Expression as an Indicator for the Treatment of Cancer
12/15/2011	US20110306564 Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
12/15/2011	US20110306563 Macrolactone derivatives, method for the production thereof and use thereof for the treatment of cancer
12/15/2011	US20110306562 Antisense EGFRAS Guanidinium Peptide Nucleic Acid (GPNA) Oligonucleotides as Antitumor Agents
12/15/2011	US20110306560 Boronic ester and acid compounds, synthesis and uses
12/15/2011	US20110306544 Methods and formulations for increasing intestinal function
12/15/2011	US20110306539 Process for making particles for delivery of drug nanoparticles
12/15/2011	US20110306057 Phosphorylated RalA
12/15/2011	US20110306040 Cpg receptor (cpg-r) and methods relating thereto
12/15/2011	US20110305782 Methods of cholesterol reduction using isoflavones
12/15/2011	US20110305777 Dimeric iap antagonists
12/15/2011	US20110305771 Krill Extracts for Treatment of Cardiovascular Diseases
12/15/2011	US20110305770 Releasable polymeric lipids for nucleic acids delivery system
12/15/2011	US20110305769 Branched cationic lipids for nucleic acids delivery system
12/15/2011	US20110305768 Quick-dissolving oral thin film for targeted delivery of therapeutic agents
12/15/2011	US20110305765 Preparation and methodology of silk fibroin nanoparticles
12/15/2011	US20110305762 Pharmaceutical composition comprising n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4- quinazolinamine
12/15/2011	US20110305750 Membrane type-1 matrix metalloprotein inhibitors and uses thereof
12/15/2011	US20110305743 Ocular implant made by a double extrusion process
12/15/2011	US20110305734 Nucleic acid nanoparticles and uses therefor
12/15/2011	US20110305731 Pharmaceutical formulation between jasmonates and it derivatives and nanocarries or microcarries
12/15/2011	US20110305730 Mono-and disaccharide derivatives
12/15/2011	US20110305729 Scriptaid Isosteres and Their Use in Therapy
12/15/2011	US20110305724 Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof
12/15/2011	US20110305723 Molecular Antigen Array
12/15/2011	US20110305722 Mage-c2 antigenic peptides and uses thereof
12/15/2011	US20110305716 Targeted cytokine for treatment of diseases
12/15/2011	US20110305714 Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
12/15/2011	US20110305712 Ctla4 proteins and their uses
12/15/2011	US20110305707 Compositions and methods for treating cancer
12/15/2011	US20110305703 Isolated vegf-c and vegf-d peptides and uses thereof
12/15/2011	US20110305699 Treating Oral Cancer with Anti-IL-20 Antibody
12/15/2011	US20110305698 Treating Breast Cancer and Inhibiting Cancer-Associated Bone loss with Anti-IL-20 Antibody
12/15/2011	US20110305695 Wnt Antagonists and Methods of Treatment and Screening
12/15/2011	US20110305694 Multivalent and/or multispecific rankl-binding constructs
12/15/2011	US20110305693 Anitigen-binding constructs
12/15/2011	US20110305690 Antitumor combinations containing antibodies recognizing specifically cd38 and cyclophosphamide
12/15/2011	US20110305687 Anti-fgfr2 antibodies
12/15/2011	US20110305685 Supramolecular approach for preparation of size controllable nanoparticles
12/15/2011	US20110305684 Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
12/15/2011	US20110305680 Composition Containing Osteopontin for Differentiating Natural Killer Cell as an Active Ingredient and a Method of Differentiation Using Thereof
12/15/2011	US20110305667 Use of a dead-box rna helicase for inducing cytokine production
12/15/2011	US20110305661 Carbazole Compounds and Therapeutic Uses of the Compounds
12/15/2011	US20110305639 Method and formulation for reducing aggregation of a macromolecule under physiological conditions
12/15/2011	US20110305636 Compounds, compositions, methods of synthesis, and methods of treatment
12/15/2011	US20110305634 Methods and systems for adenovirus interaction with desmoglein 2 (DSG2)
12/15/2011	US20110305633 Methods for Treatment, the Prognostic Assessment and the Detection of Breast Cancer
12/15/2011	US20110305632 Process for the preparation of asymmetrical bis(thiosemicarbazones)
12/15/2011	US20110305631 Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases
12/15/2011	US20110305630 Misfolded proteins in cancer treatment and diagnosis
12/15/2011	US20110305629 Anti-Alpha v Beta 6 Antibodies and Uses Thereof
12/15/2011	DE102010026883A1 Transdermal system useful e.g. for indication of breast cancer with progesterone-receptor positive status, comprises e.g. aromatase inhibitor, active substance puller protection layer, active substance reservoir
12/15/2011	DE102009041242A1 New heterocyclically substituted aryl compounds are hypoxia-inducible factor inhibitors useful to treat and/or prevent e.g. cancer or tumor diseases, ischemic cardiovascular diseases, heart attack, arrhythmia, stroke, and psoriasis
12/15/2011	CA2802484A1 Methods of treating hematological disorders with quinazolinone compounds in selected patients
12/15/2011	CA2802130A1 Cyanoquinoline derivatives
12/15/2011	CA2802064A1 Crystalline forms of kinase inhibitors
12/15/2011	CA2802042A1 Crystalline forms of kinase inhibitors
12/15/2011	CA2802029A1 Crystalline forms of kinase inhibitors
12/15/2011	CA2801939A1 Pyrrolyl substituted dihydroindol-2-one derivatives, preparation methods and uses thereof
12/15/2011	CA2801922A1 Multivalent glycopeptide constructs and uses thereof
12/15/2011	CA2801891A1 Combination therapy methods for treating proliferative diseases
12/15/2011	CA2801778A1 Furanyl compounds and the use thereof
12/15/2011	CA2801631A1 Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
12/15/2011	CA2800911A1 Immunogenic vaccine
12/15/2011	CA2800673A1 Estrogen receptor modulators and uses thereof
12/15/2011	CA2800203A1 Morpholino pyrimidines and their use in therapy
12/15/2011	CA2799076A1 Anti-tumor composition
12/15/2011	CA2799022A1 Nitrogen containing heteroaryl compounds
12/15/2011	CA2798837A1 Her-2 peptides and vaccines
12/15/2011	CA2798143A1 Compound, synthesis, composition and uses thereof
12/14/2011	EP2395024A2 Modified antigen binding molecules with altered cell signaling activity
12/14/2011	EP2395023A2 Modified antigen binding molecules with altered cell signaling activity
12/14/2011	EP2395007A1 Fractionated products obtained from gamboge resin, and medical uses of the same
12/14/2011	EP2395006A1 Novel compounds obtained from gamboge resin, and medical uses of the same
12/14/2011	EP2395005A1 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
12/14/2011	EP2395004A2 Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors
12/14/2011	EP2395001A1 Novel pyrimidine derivatives
12/14/2011	EP2395000A1 Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
12/14/2011	EP2394702A1 Compounds and methods for the treatment of cancer
12/14/2011	EP2394660A1 Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
12/14/2011	EP2394659A1 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
12/14/2011	EP2394655A2 Epitope sequences
12/14/2011	EP2394652A2 Methods and compositions for treating tumors and metastatic disease
12/14/2011	EP2394650A1 Use of resiquimod for the treatment of cutaneous metastases
12/14/2011	EP2394649A1 Pharmaceutical compositions containing pyridyl cyanoguanidines, preparation methods and uses thereof
12/14/2011	EP2393854A2 Nanoscale platinum compounds and methods of use thereof
12/14/2011	EP2393836A1 Sam-6 variants, target and methods of use
12/14/2011	EP2393827A1 Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
12/14/2011	EP2393826A2 Novel saponin compounds, methods of preparation thereof, use thereof and pharmaceutical compositions
12/14/2011	EP2393818A2 Triptolide c-ring derivatives as anticancer agents and immune modulators
12/14/2011	EP2393815A2 Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
12/14/2011	EP2393814A1 Pyrrolopyrimidinyl axl kinase inhibitors
12/14/2011	EP2393809A2 Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
12/14/2011	EP2393801A2 Indole derivatives as anticancer agents
12/14/2011	EP2393794A1 Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
12/14/2011	EP2393793A1 Derivatives of 6-(6-substituted-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
12/14/2011	EP2393792A1 Derivatives of 6-(6-nh-substituted-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors

1 ... 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 ... 2211